Replies to post #128 on TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

That's a nice update, thanks for posting that. Impressive institutional involvement, imo.

The category of TCR-T, is still relatively new imo, with little in vivo data available to date.

For information purposes, Kimmtrack was the first FDA approved TCR-T in January of 2022 and there is an interesting read here :

https://acgtfoundation.org/news/explaining-t-cell-receptor-therapy-for-cancer/